# Prediction of Bleeding Risk After Anticoagulant Therapy for Atrial Fibrillation Based on Proteomics and Metabolomics

> **NCT05181774** · — · UNKNOWN · sponsor: **Yue LI** · enrollment: 100 (estimated)

## Conditions studied

- Atrial Fibrillation
- Bleeding
- Anticoagulant Therapy

## Interventions

- **DIAGNOSTIC_TEST:** Proteomics
- **DIAGNOSTIC_TEST:** Metabolomics

## Key facts

- **NCT ID:** NCT05181774
- **Lead sponsor:** Yue LI
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-20
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05181774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05181774, "Prediction of Bleeding Risk After Anticoagulant Therapy for Atrial Fibrillation Based on Proteomics and Metabolomics". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05181774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*